Budesonide MMX® 9 mg probably leads to higher remission (combined clinical and endoscopic remission) compared with placebo (moderate certainty).
Budesonide MMX® 6 mg showed no clear difference in endoscopic improvement compared with placebo (moderate certainty).
Budesonide MMX® 6 mg showed no clear difference in histologic remission compared with placebo (low certainty).
Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).
It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide 10 mg showed no clear difference in endoscopic improvement compared with prednisolone 40 mg (low certainty).
It is very uncertain whether budesonide 10 mg changes endoscopic remission compared with prednisolone 40 mg (very low certainty).
It is very uncertain whether budesonide 10 mg changes histologic remission compared with prednisolone 40 mg (very low certainty).
It is very uncertain whether budesonide 10 mg changes adverse event ‐ Reduction in plasma cortisol below lower reference… compared with prednisolone 40 mg (very low certainty).
It is very uncertain whether budesonide 10 mg changes study withdrawals compared with prednisolone 40 mg (very low certainty).
Budesonide MMX® 9 mg showed no clear difference in clinical improvement compared with placebo (moderate certainty).
It is very uncertain whether budesonide 10 mg changes withdrawal due to adverse event compared with prednisolone 40 mg (very low certainty).
Budesonide probably leads to lower clinical remission (ITT analysis) compared with mesalamine (moderate certainty).
Budesonide probably leads to lower endoscopic improvement Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in endoscopic remission (EI ≤ 1) compared with mesalamine (moderate certainty).
Budesonide probably leads to lower histologic remission Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).
Budesonide showed no clear difference in remission (combined clinical and endoscopic remission) compared with mesalamine (low certainty).
Budesonide showed no clear difference in clinical improvement compared with mesalamine (moderate certainty).